Lung cancer (Amsterdam, Netherlands)HumansCarcinomaNon-Small-Cell LungMaleFemale
Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapy.
Adam Khorasanchi, Mingjia Li, Songzhu Zhao, Lai Wei, Evelyn Goodyear, Kevin Ho, Hamzah Abu-Sbeih, Austin Secor, Erin M Bertino, Peter G Shields, Logan Roof, Jinesh Gheeya, Kai He, Jacob Kaufman, Regan Memmott
Published: 202510.1016/j.lungcan.2025.108832
Abstract
BACKGROUND: Patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) are at risk for severe immune-related adverse events (irAEs). Limited data exists on the association between severe irAEs requiri…
Preview only. Read the full abstract at the source